Literature DB >> 18057733

Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice.

Yumi Sugimoto1, Noriko Tagawa, Yoshiharu Kobayashi, Yoshihiro Hotta, Jun Yamada.   

Abstract

The effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor (SNRI) on the obsessive compulsive disorder (OCD) model, marble burying behavior, were investigated in mice. Milnacipran above the dosage of 10 mg/kg inhibited marble burying behavior significantly in mice as similar to fluvoxamine. Milnacipran inhibiting marble burying behavior did not affect locomotor activity. These results suggest that milnacipran can inhibit marble burying behavior and that milacipran may be useful for OCD therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057733     DOI: 10.1248/bpb.30.2399

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  11 in total

1.  Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.

Authors:  Nancy A Shanahan; Lady P Velez; Virginia L Masten; Stephanie C Dulawa
Journal:  Biol Psychiatry       Date:  2011-09-13       Impact factor: 13.382

Review 2.  A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward.

Authors:  Geoffrey de Brouwer; Arina Fick; Brian H Harvey; De Wet Wolmarans
Journal:  Cogn Affect Behav Neurosci       Date:  2019-02       Impact factor: 3.282

3.  Perinatal exposure to FireMaster® 550 (FM550), brominated or organophosphate flame retardants produces sex and compound specific effects on adult Wistar rat socioemotional behavior.

Authors:  Shannah K Witchey; Loujain Al Samara; Brian M Horman; Heather M Stapleton; Heather B Patisaul
Journal:  Horm Behav       Date:  2020-09-23       Impact factor: 3.587

4.  Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity.

Authors:  Van A Doze; Robert S Papay; Brianna L Goldenstein; Manveen K Gupta; Katie M Collette; Brian W Nelson; Mariaha J Lyons; Bethany A Davis; Elizabeth J Luger; Sarah G Wood; James R Haselton; Paul C Simpson; Dianne M Perez
Journal:  Mol Pharmacol       Date:  2011-07-26       Impact factor: 4.436

5.  SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2011-06

6.  Opposite effects of milnacipran, a serotonin norepinephrine reuptake inhibitor, on the levels of nitric oxide and brain-derived neurotrophic factor in mouse brain cortex.

Authors:  Atsuko Ikenouchi-Sugita; Yumiko Toyohira; Reiji Yoshimura; Susumu Ueno; Masato Tsutsui; Jun Nakamura; Nobuyuki Yanagihara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-06       Impact factor: 3.000

7.  alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.

Authors:  Van A Doze; Evelyn M Handel; Kelly A Jensen; Belle Darsie; Elizabeth J Luger; James R Haselton; Jeffery N Talbot; Boyd R Rorabaugh
Journal:  Brain Res       Date:  2009-06-18       Impact factor: 3.252

8.  Central norepinephrine transmission is required for stress-induced repetitive behavior in two rodent models of obsessive-compulsive disorder.

Authors:  Daniel Lustberg; Alexa F Iannitelli; Rachel P Tillage; Molly Pruitt; L Cameron Liles; David Weinshenker
Journal:  Psychopharmacology (Berl)       Date:  2020-04-20       Impact factor: 4.530

9.  Literature mining for the discovery of hidden connections between drugs, genes and diseases.

Authors:  Raoul Frijters; Marianne van Vugt; Ruben Smeets; René van Schaik; Jacob de Vlieg; Wynand Alkema
Journal:  PLoS Comput Biol       Date:  2010-09-23       Impact factor: 4.475

10.  Ameliorating effects of gypenosides on chronic stress-induced anxiety disorders in mice.

Authors:  Ting Ting Zhao; Keon Sung Shin; Hyun Sook Choi; Myung Koo Lee
Journal:  BMC Complement Altern Med       Date:  2015-09-14       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.